e-Therapeutics names Daniel Elger CFO.
M2 PHARMA-June 13, 2011-e-Therapeutics names Daniel Elger CFO(C)2011 M2 COMMUNICATIONS
13 June 2011 - UK-based e-Therapeutics plc (LON: ETX) said today it has named Dr Daniel Elger chief financial officer and board member.
Dr Elger was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc (LON: ASM). He joined that company in 2002 and served on its senior management team from 2005. He also directed the investor relations strategy for the company.
Prior to Antisoma, Dr Elger was a Programme director for major pharmaceutical companies at a marketing and communications agency. He holds a BA in Physiological Sciences (Medicine) and a PhD in cancer cell biology, both from Oxford University.
The company also announced the departure of J.M. Cordiner from his position as finance director of e-Therapeutics and from the board on 10 June, in order to pursue other business interests.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 13, 2011|
|Previous Article:||Valeant, GlaxoSmithKline say FDA greenlights Potiga.|
|Next Article:||FDA okays redesigned labels for certain Merck drugs.|